234 results on '"Tiedemann, Rodger"'
Search Results
2. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
3. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
4. Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience
5. OA-25 MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells
6. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
7. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
8. Data from Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
9. Supplementary Data from Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
10. Supplementary Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
11. Table S2 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
12. Data from Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
13. Supplementary Table 1 from Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
14. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression
15. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
16. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
17. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
18. Correction to “Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma”
19. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains
20. Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
21. Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma
22. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
23. sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution
24. OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers
25. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis
26. Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma
27. Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults
28. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
29. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
30. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
31. Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma
32. Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
33. Simultaneous Profiling of DNA Copy Number Variations and Transcriptional Programs in Single Cells using RNA-seq
34. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
35. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
36. sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution.
37. Syngeneic transplants for multiple myeloma – a single center experience and review of the literature
38. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines
39. sciCNV: High-throughput paired profiling of transcriptomes and DNA copy number variations at single cell resolution
40. Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
41. Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
42. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
43. Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?
44. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
45. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
46. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients
47. Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience
48. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma
49. 47 - Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
50. Abstract 2377: Design, synthesis, and characterization of 4-aminopyrazole quinazolines as potent inhibitors of G protein-coupled receptor kinase GRK6 for the potential treatment of multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.